Management Team

Professor Andrew Wilks

Professor Andrew Wilks

Co-founder and Executive Chairman

Andrew Wilks PhD has been involved as a scientist in pharmaceutical drug discovery for 3 decades, most recently as Chief Scientific Officer and founder of Cytopia. Prior to starting Cytopia, Andrew was an accomplished scientist at the Ludwig institute for Cancer Research in Melbourne where he discovered the JAK kinases and published 1 book, 86 peer reviewed publications, and 35 patents and patent applications. Andrew is a member of the board and/or scientific advisory board of a number of research companies, holds an Honorary Professorship in the Department of Medicine, Nursing and Health Sciences at Monash University (Melbourne).

Dr. Xian Bu

Dr. Xian Bu

Co-founder and Managing Director

Xian is Managing Director of SYNthesis operations, including the company’s wholly-owned Chinese subsidiary in Shanghai, where he leads our principal synthetic and medicinal chemistry team. Xian previously served as Vice President for the Chinese chemistry service company, SynCores, and was a Senior Drug Discovery Scientist at Cytopia. Xian has a proven capability in the management of a CRO company, rich experience in project management and real expertise in medicinal and synthetic chemistry. He also has an outstanding track record in the drug discovery and development area, especially in design and development of small molecules as drugs for oncology and cardiovascular diseases.

Dr. John Feutrill

Dr. John Feutrill

VP of Medicinal Chemistry

Dr John Feutrill is our VP med chem, and runs the majority of our European med chem programmes. John was a senior post-doctoral chemist at Cytopia, where he was a key contributor to their collaboration with Novartis, as well as the clinical phase compound CYT387.

Dr. Anthony Cuzzupe

Dr. Anthony Cuzzupe

Director of Medicinal Chemistry

Dr Anthony Cuzzupe joined SYNthesis med chem early in 2010 and is the company’s Director of Medicinal Chemistry, managing a number of FTE programs for both domestic and foreign clients. Prior to joining SYNthesis, Anthony occupied a leading medicinal chemistry role at Melbourne biotech, Cytopia, developing small molecule JAK 3 inhibitors in a Novartis-partnered JAK 3 program. Anthony obtained his PhD in natural product total synthesis from the University of Melbourne and has completed a 2-year post-doctoral appointment with Prof Peter Wipf at the University of Pittsburgh, working in total synthesis and methodology development.